Nina Schöbi

Nina Schöbi

Auto-generated profile, based on publicly available information

Nina Schöbi

Inselspital, Bern University Hospital, University of Bern

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in Infection
Verified
Journal Article
Open access
PDF file
NSNina Schöbi
Nina Schöbi
ADAndrea Duppenthaler
Andrea Duppenthaler
MHMatthias Horn
Matthias Horn
ABAndreas Bartenstein
Andreas Bartenstein
KKKristina Keitel
Kristina Keitel
CAChristoph Aebi
Christoph Aebi
Purpose: The massive increase of infections with Group A Streptococcus (GAS) in 2022–2023 coincided in Switzerland with a change of the recommendations for the management of GAS pharyngitis. Therefore, the objective of the present study was to investigate whether the clinical manifestations and management before hospitalization for GAS infection differed in 2022–2023 compared with 2013–2022. Methods: Retrospective study of GAS infections requiring hospitalization in patients below 16 years. Preadmission illness (modified McIsaac score), oral antibiotic use, and outcome in 2022–2023 were compared with 2013–2022. Time series were compared with surveillance data for respiratory viruses. Results: In 2022–2023, the median modified McIsaac score was lower (2 [IQR 2–3] vs. 3 [IQR 2–4], p = < 0.0001) and the duration of preadmission illness was longer (4 days [3–7] vs. 3 [2–6], p = 0.004) than in 2013–2022. In both periods, withholding of preadmission oral antibiotics despite a modified McIsaac score ≥ 3 (12% vs. 18%, n.s.) or ≥ 4 (2.4% vs. 10.0%, p = 0.027) was rare. Respiratory disease, skeletal/muscle infection, and invasive GAS disease were significantly more frequent in 2022–2023, but there were no differences in clinical outcome. The time course of GAS cases in 2022–2023 coincided with the activity of influenza A/B. Conclusion: We found no evidence supporting the hypothesis that the 2022–2023 GAS outbreak was associated with a change in preadmission management possibly induced by the new recommendation for GAS pharyngitis. However, clinical manifestations before admission and comparative examination of time-series strongly suggest that viral co-circulation played an important role in this outbreak.

1 November 2024 in Swiss Medical Weekly
Verified
Journal Article
Open access
PDF file
CAChloé Alberto
Chloé Alberto
NWNoémie Wagner
Noémie Wagner
YFYves Fougère
Yves Fougère
PSPatrick M. Meyer Sauteur
Patrick M. Meyer Sauteur
GSGioia Scherler
Gioia Scherler
LTLaurence Toutous Trellu
Laurence Toutous Trellu
BACKGROUND AND AIMS OF THE STUDY: Congenital syphilis is a rare complication of syphilis in pregnant women. Vertical transmission may occur at any time during pregnancy. The incidence of congenital syphilis has been increasing worldwide. Congenital syphilis has been a notifiable disease for many years in Switzerland but reporting does not include maternal features associated with syphilis in pregnancy or infantʼs subsequent development. We described syphilis cases among pregnant women screened over a 10-year period in Switzerland and subsequent cases of congenital syphilis, in order to identify maternal risk profiles and to optimise prevention. Second, we compared the characteristics of pregnant women screened early (1st trimester) vs late in pregnancy (2nd or 3rd trimester). Finally, we assessed the risk factors for premature birth among these women with syphilis. METHODS: A multicentre retrospective study conducted in Swiss hospitals from 2012 to 2021, including pregnant women who screened positive for syphilis (Treponema pallidum haemagglutination assay [TPHA] / T. pallidum particle agglutination assay [TPPA ] ≥1:80) and newborns exposed to T. pallidum in utero and/or congenitally infected and with a positive syphilis serology at birth. Data were collected from medical records. RESULTS: A total of 147 syphilis-positive pregnant women and 102 infants were included. A history of treated syphilis was known for 44% (65/147) of the mothers corresponding to a serological scar and the remaining 56% (82/147) were newly identified syphilis cases. Syphilis screening was done during the first trimester in 54%, second trimester in 29% and third trimester in 13% of cases. Two babies were diagnosed with congenital syphilis (1.96%). Several potential factors that could contribute to women’s risk of syphilis during pregnancy were identified such as a foreign origin (93% of mothers), lack of healthcare insurance (25%), no employment status (37%), drug use (5%), co-infection with other sexually transmitted infections (24%) and a late first antenatal consultation (42%). The number of pregnant women without insurance was higher in women diagnosed in the second or third trimester than in those diagnosed in the first trimester (odds ratio 0.41; 95% CI 0.19–0.89; p = 0.024). Syphilis diagnosed in the second or third trimester was associated with a late first antenatal consultation (odds ratio 77.82; 95% CI 9.81–617.21; p <0.001). A high rate of intrauterine growth retardation and of preterm birth was observed in newborns (18% versus 6% in Switzerland in 2022). CONCLUSION: Congenital syphilis remains rare in Switzerland. However, we found potential maternal factors associated with a positive syphilis serology during pregnancy, which can help to improve future prevention measures. The study protocol was registered on ClinicalTrials.gov (ID NCT05975502).

10 August 2022 in Klinische Padiatrie
Verified
Journal Article
Open access
PDF file
NSNina Schöbi
Nina Schöbi
KKKristin Kernland
Kristin Kernland
Matthias Volkmar MatthiasMatthias Volkmar Matthias
Matthias Volkmar Matthias
CAChristoph Aebi
Christoph Aebi
Kawasaki disease (KD) is an acute systemic inflammatory illness causing vasculitis. A diffuse polymorphous rash is one of the predominant features of patients presenting with KD. This rash can have a morbilliform, urticarial, micropustular, or further unspecific morphology. Psoriasis-like eruptions following KD were first described by Han et al. 2000 (Han M H et al., Br J Dermatol 2000; 142: 548–550), thereafter several case reports – describing over 30 children worldwide – have been published. It usually consists of a single episode with enduring remission, contrasting typical psoriasis. Furthermore, the eruptions can have an atypical presentation with less involvement of the anogenital area and more serous crusting (Haddock E S et al., J Am Acad Dermatol 2016; 75: 69–76), (Eberhard B A et al., J Pediatr 2000; 137, 4: 578–580). It is a well-known entity amongst dermatologists. However, acknowledgement by the paediatric community is limited. This is also reflected by the fact that 11 publications can be found in a dermatological journal versus 4 publications in a paediatric journal. Article published online: 10 August 2022 © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

25 April 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
NSNina Schöbi
Nina Schöbi
CSCarlos Sanchez
Carlos Sanchez
TWTatjana Welzel
Tatjana Welzel
ABAlasdair Bamford
Alasdair Bamford
KWKate Webb
Kate Webb
JBJulia Anna Bielicki
Julia Anna Bielicki
Objectives In trials of acute severe infections or inflammations frequent administration of non-randomised treatment (ie, intercurrent event) in response to clinical events is expected. These events may affect the interpretation of trial findings. Swissped-RECOVERY was set up as one of the first randomised controlled trials worldwide, investigating the comparative effectiveness of anti-inflammatory treatment with intravenous methylprednisolone or intravenous immunoglobulins in children and adolescents with Paediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS). We present one approach towards improving the interpretation of non-randomised treatment in a randomised controlled trial. Design This is a pre-planned ancillary analysis of the Swissped-RECOVERY trial, a randomised multicentre open-label two-arm trial. Setting 10 Swiss paediatric hospitals (secondary and tertiary care) participated. Participants Paediatric patients hospitalised with PIMS-TS. Interventions All patient-first intercurrent events, if applicable, were presented to an independent adjudication committee consisting of four international paediatric COVID-19 experts to provide independent clinical adjudication to a set of standardised questions relating to whether additional non-randomised treatments were clinically indicated and disease classification at the time of the intercurrent event. Results Of 41 treatments in 75 participants (24/41 (59%) and 17/41 (41%) in the intravenous methylprednisolone and immunoglobulin arms of the trial, respectively), two-thirds were considered indicated. The most common treatment (oral glucocorticoids, 14/41, 35%) was mostly considered not indicated (11/14, 79%), although in line with local guidelines. Intercurrent events among patients with Shock-like PIMS-TS at baseline were mostly considered indicated. A significant proportion of patients with undifferentiated PIMS-TS at baseline were not attributed to the same group at the time of the intercurrent event (6/12 unchanged, 4/12 Kawasaki disease-like, 2/12 Shock-like). Conclusion The masked adjudication of intercurrent events contributes to the interpretation of results in open-label trials and should be incorporated in the future. Trial registration numbers SNCTP000004720 and NCT 04826588.

14 October 2025 in Infection
Verified
Journal Article
Open access
PDF file
LBLeonie Bregy
Leonie Bregy
PAPhilipp K.A. Agyeman
Philipp K.A. Agyeman
ADAndrea Duppenthaler
Andrea Duppenthaler
EKElisabeth Kieninger
Elisabeth Kieninger
MHMatthias Horn
Matthias Horn
NSNina Schöbi
Nina Schöbi
Purpose: Paediatric parapneumonic effusion (PPE) is accompanied by an increased risk of complications, e.g., sepsis or lung sequelae. Treatment strategies span from antibiotics alone to surgical interventions, but an internationally accepted guideline is lacking. With this study, we aim to better understand how management strategies influence short-term outcome parameters, like length of stay, antibiotic treatment duration, and lung damage. Methods: Retrospective observational single-centre study. Patients admitted from 1 July 2004 to 30 June 2024 with PPE to our tertiary hospital were analysed. We used the exact Jonckheere-Terpstra test to analyse trends over time. Results: A total of 278 patients were included, 23 (8%) had to be excluded for lack of informed consent. A majority (173/255, 68%) were treated with pleural drainage. Over time, drains were increasingly more often inserted without surgery, 20% vs. 65% ( p = 0.001) in 2004–2008 vs. 2020–2024. Intravenous antibiotic treatment duration declined from 15 days in 2004–2008 to 11 days in 2020–2024, p = 0.002. The most commonly identified pathogen was S. pneumoniae (39%), followed by S. pyogenes (18%). S. pyogenes compared to S. pneumoniae was more often associated with sepsis or toxic shock (45% vs. 6%, p < 0.0001), but fewer patients showed radiologic evidence for acute lung damage (68% vs. 23%, p < 0.001). Conclusion: We found considerable clinical differences in patients with PPE caused by S. pneumoniae vs. S. pyogenes. The former was associated with substantially greater lung damage.

2 September 2024 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
NSNina Schöbi
Nina Schöbi
ADAndrea Duppenthaler
Andrea Duppenthaler
MHMatthias Horn
Matthias Horn
ABAndreas Bartenstein
Andreas Bartenstein
KKKristina Keitel
Kristina Keitel
CAChristoph Aebi
Christoph Aebi
A Europe-wide outbreak of invasive pediatric group A streptococcal infections (iGAS) began in fall 2022. Here, we report the evolution of GAS hospitalizations in children and adolescents during the second outbreak year in 2023–2024 at a tertiary center in Switzerland. Using prospective monitoring of all in-patient GAS cases below 16 years of age, including those with iGAS, we compared case frequencies and clinical characteristics in three time periods (2013–2020; 2022–2023; 2023–2024). Annual GAS hospitalizations increased from a median of 25 cases (range 11–28) in 2013–2020 to 89 and 63 cases, respectively, in 2022–2023 and 2023–2024. iGAS cases evolved similarly (2013–2020, 4 cases (3–8); 2022–2023, 32 cases; 2023–2024, 21 cases). The decline in cases from 2022–2023 to 2023–2024 included all types of GAS organ involvement, except suppurative infections in the head area, which remained largely unchanged (48 vs. 45 cases). Pleural empyema declined from 13 to 7 cases, possibly explained by a poor overlap of the GAS and influenza curves, respectively, in 2023–2024 compared to 2022–2023. These data document the prolongation of the GAS outbreak into its second winter season in 2023–2024.